EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

One‐month DAPT after biodegradable‐polymer everolimus‐eluting stent implantation in women at high‐bleeding risk: Insights from the POEM trial

Matteo Maurina iD, Carlo Andrea Pivato iD, Vijay Kunadian, Luca Testa iD, Carlo Briguori iD, Andrea Pacchioni iD, Alessia Chiara Latini, Nicola Cesani, Raffale Piccolo iD, Carmine Musto, Gennaro Sardella, Ciro Indolfi und 3 weitere

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.31255 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Matteo Maurina und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Drug-Eluting Stents, Everolimus, Absorbable Implants. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We conducted a prespecified subanalysis of the POEM trial to assess the association between sex and clinical outcomes following a short 1‐month dual‐antiplatelet‐therapy (DAPT) period after percutaneous coronary intervention (PCI) with bioresorbable polymer everolimus‐eluting stent (BP‐EES) among patients at high bleeding risk (HBR).

Background

Shortening the DAPT period after PCI is an effective bleeding avoidance strategy with contemporary drug‐eluting stents. Whether sex affects the risk of adverse events following PCI is still debated.

Methods

Patients at HBR undergoing PCI with BP‐EES were enrolled and treated with 1‐month DAPT. If anticoagulation was needed, study participants received an oral anticoagulant (OAC) in addition to a P2Y 12 inhibitor for 1 month, followed by OAC only thereafter. The primary endpoint was a composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis at 12 months. We report sex‐based outcomes of patients included in the POEM study.

Results

We enrolled 129 (29.1%) women and 314 (70.9%) men. Women were older, with lower hemoglobin levels, and worse renal function. Accordingly, they had a trend for a greater number of HBR criteria fulfilled and a higher PARIS bleeding score. However, they were not at a significantly higher risk for the primary endpoint (men vs. women: 5.17% vs. 3.94%; HR 1.30; 95% CI: 0.48‐3.54, p = 0.61), or any of the hemorrhagic and ischemic secondary endpoints.

Conclusions

This prespecified subanalysis of the POEM trial suggests that 1‐month DAPT following PCI with BP‐EES may be a safe and effective therapeutic strategy for women at HBR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionDrug-Eluting StentsEverolimusAbsorbable ImplantsProsthesis DesignDual Anti-Platelet TherapyHemorrhagePlatelet Aggregation InhibitorsCoronary Artery DiseaseDrug Administration ScheduleHumansFemaleMaleAgedTime FactorsRisk FactorsMiddle AgedTreatment OutcomeRisk AssessmentSex FactorsCoronary ThrombosisPurinergic P2Y Receptor AntagonistsAnticoagulantsProspective StudiesAdministration, Oral

Stichwörter der Autor:innen

biodegradable polymerhigh bleeding riskpercutaneous coronary interventionsexshort DAPTwomen

Substanzen

EverolimusPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAnticoagulants

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy.
  • Cardio Center, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan, Italy.
  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Medical School, Newcastle upon Tyne, UK.
  • Cardiothoracic Centre, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
  • IRCCS Policlinico San Donato, Milan, Italy.
  • Mediterranea Cardiocentro, Naples, Italy.

ORCID-Profile: Matteo Maurina, Carlo Andrea Pivato, Luca Testa, Carlo Briguori, Andrea Pacchioni, Raffale Piccolo, Giulio Stefanini

Förderung

  • Boston Scientific Corporation

Zitieren

APA

Maurina, M., Pivato, C. A., Kunadian, V., Testa, L., Briguori, C., Pacchioni, A., Latini, A. C., Cesani, N., Piccolo, R., Musto, C., Sardella, G., Indolfi, C., Regazzoli, D., Paradies, V., & Stefanini, G. (2024). One‐month DAPT after biodegradable‐polymer everolimus‐eluting stent implantation in women at high‐bleeding risk: Insights from the POEM trial. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31255

Vancouver

Maurina M, Pivato CA, Kunadian V, Testa L, Briguori C, Pacchioni A, et al. One‐month DAPT after biodegradable‐polymer everolimus‐eluting stent implantation in women at high‐bleeding risk: Insights from the POEM trial. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31255

BibTeX
@article{Maurina2024,
  author = {Maurina, Matteo and Pivato, Carlo Andrea and Kunadian, Vijay and Testa, Luca and Briguori, Carlo and Pacchioni, Andrea and Latini, Alessia Chiara and Cesani, Nicola and Piccolo, Raffale and Musto, Carmine and Sardella, Gennaro and Indolfi, Ciro and Regazzoli, Damiano and Paradies, Valeria and Stefanini, Giulio},
  title = {One‐month DAPT after biodegradable‐polymer everolimus‐eluting stent implantation in women at high‐bleeding risk: Insights from the POEM trial},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.31255}
}
Kostenlos starten →